Cargando…
Effect of triple therapy in patients with asthma-COPD overlap
Objective: Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is of increasing interest because ACO patients have significantly worse outcomes, leading to greater social and economic burdens compared with asthma or COPD alone. Some guidelines for ACO recommend triple therapy with inha...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637394/ https://www.ncbi.nlm.nih.gov/pubmed/31232275 http://dx.doi.org/10.5414/CP203382 |
_version_ | 1783436235507761152 |
---|---|
author | Ishiura, Yoshihisa Fujimura, Masaki Ohkura, Noriyuki Hara, Johsuke Kasahara, Kazuo Ishii, Nobuyasu Tamaki, Takeshi Shimizu, Toshiki Nomura, Shosaku |
author_facet | Ishiura, Yoshihisa Fujimura, Masaki Ohkura, Noriyuki Hara, Johsuke Kasahara, Kazuo Ishii, Nobuyasu Tamaki, Takeshi Shimizu, Toshiki Nomura, Shosaku |
author_sort | Ishiura, Yoshihisa |
collection | PubMed |
description | Objective: Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is of increasing interest because ACO patients have significantly worse outcomes, leading to greater social and economic burdens compared with asthma or COPD alone. Some guidelines for ACO recommend triple therapy with inhaled corticosteroids, long-acting β2 agonists, and long-acting muscarinic antagonists. However, this approach is based on extrapolating data from patients with asthma or COPD alone. Therapeutic studies for ACO have not previously been conducted. Materials and methods: A 12-week, randomized, open-label cross-over pilot study was conducted in 17 ACO patients to evaluate the effect of umeclidinium (UMEC) 62.5 µg once-daily added to fluticasone furoate/vilanterol (FF/VI) 200/25 µg once-daily. A 4-week run-in, a first and a second 4-week treatment period were included. Respiratory function, respiratory impedance, fractional exhaled nitric oxide, COPD assessment test, and asthma control test scores were evaluated 0, 4, and 8 weeks after randomization. Results: Mean values of post-bronchodilator forced expiratory volume in 1 second as a percentage of the predicted value (%FEV(1)), after UMEC was added to FF/VI, were significantly higher than after the run-in (p < 0.01). Mean values of resonant frequency during inspiration (Fres), after UMEC was added to FF/VI, were significantly lower than after the run-in (p < 0.01). Conclusion: Adding UMEC to FF/VI provides greater improvement in lung function, indicating that triple therapy is a suitable regular treatment for ACO. |
format | Online Article Text |
id | pubmed-6637394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dustri-Verlag Dr. Karl Feistle |
record_format | MEDLINE/PubMed |
spelling | pubmed-66373942019-08-02 Effect of triple therapy in patients with asthma-COPD overlap Ishiura, Yoshihisa Fujimura, Masaki Ohkura, Noriyuki Hara, Johsuke Kasahara, Kazuo Ishii, Nobuyasu Tamaki, Takeshi Shimizu, Toshiki Nomura, Shosaku Int J Clin Pharmacol Ther Research Article Objective: Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is of increasing interest because ACO patients have significantly worse outcomes, leading to greater social and economic burdens compared with asthma or COPD alone. Some guidelines for ACO recommend triple therapy with inhaled corticosteroids, long-acting β2 agonists, and long-acting muscarinic antagonists. However, this approach is based on extrapolating data from patients with asthma or COPD alone. Therapeutic studies for ACO have not previously been conducted. Materials and methods: A 12-week, randomized, open-label cross-over pilot study was conducted in 17 ACO patients to evaluate the effect of umeclidinium (UMEC) 62.5 µg once-daily added to fluticasone furoate/vilanterol (FF/VI) 200/25 µg once-daily. A 4-week run-in, a first and a second 4-week treatment period were included. Respiratory function, respiratory impedance, fractional exhaled nitric oxide, COPD assessment test, and asthma control test scores were evaluated 0, 4, and 8 weeks after randomization. Results: Mean values of post-bronchodilator forced expiratory volume in 1 second as a percentage of the predicted value (%FEV(1)), after UMEC was added to FF/VI, were significantly higher than after the run-in (p < 0.01). Mean values of resonant frequency during inspiration (Fres), after UMEC was added to FF/VI, were significantly lower than after the run-in (p < 0.01). Conclusion: Adding UMEC to FF/VI provides greater improvement in lung function, indicating that triple therapy is a suitable regular treatment for ACO. Dustri-Verlag Dr. Karl Feistle 2019-08 2019-06-24 /pmc/articles/PMC6637394/ /pubmed/31232275 http://dx.doi.org/10.5414/CP203382 Text en © Dustri-Verlag Dr. K. Feistle http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ishiura, Yoshihisa Fujimura, Masaki Ohkura, Noriyuki Hara, Johsuke Kasahara, Kazuo Ishii, Nobuyasu Tamaki, Takeshi Shimizu, Toshiki Nomura, Shosaku Effect of triple therapy in patients with asthma-COPD overlap |
title | Effect of triple therapy in patients with asthma-COPD overlap |
title_full | Effect of triple therapy in patients with asthma-COPD overlap |
title_fullStr | Effect of triple therapy in patients with asthma-COPD overlap |
title_full_unstemmed | Effect of triple therapy in patients with asthma-COPD overlap |
title_short | Effect of triple therapy in patients with asthma-COPD overlap |
title_sort | effect of triple therapy in patients with asthma-copd overlap |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637394/ https://www.ncbi.nlm.nih.gov/pubmed/31232275 http://dx.doi.org/10.5414/CP203382 |
work_keys_str_mv | AT ishiurayoshihisa effectoftripletherapyinpatientswithasthmacopdoverlap AT fujimuramasaki effectoftripletherapyinpatientswithasthmacopdoverlap AT ohkuranoriyuki effectoftripletherapyinpatientswithasthmacopdoverlap AT harajohsuke effectoftripletherapyinpatientswithasthmacopdoverlap AT kasaharakazuo effectoftripletherapyinpatientswithasthmacopdoverlap AT ishiinobuyasu effectoftripletherapyinpatientswithasthmacopdoverlap AT tamakitakeshi effectoftripletherapyinpatientswithasthmacopdoverlap AT shimizutoshiki effectoftripletherapyinpatientswithasthmacopdoverlap AT nomurashosaku effectoftripletherapyinpatientswithasthmacopdoverlap |